应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PDSB PDS Biotechnology Corporation
交易中 09-04 12:06:54 EDT
0.2201
+0.0001
+0.05%
最高
0.2378
最低
0.2174
成交量
79.46万
今开
0.2200
昨收
0.2200
日振幅
9.27%
总市值
1,229万
流通市值
1,197万
总股本
5,582万
成交额
17.86万
换手率
1.46%
流通股本
5,440万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
PDS生物技术公司宣布解除Stephan Toutain首席运营官职务,自2026年8月21日生效
美股速递 · 08-26
PDS生物技术公司宣布解除Stephan Toutain首席运营官职务,自2026年8月21日生效
PDS Biotechnology宣布裁员计划,优化资源配置以聚焦战略重点
美股速递 · 08-26
PDS Biotechnology宣布裁员计划,优化资源配置以聚焦战略重点
PDS Biotechnology宣布CFO Lars Boesgaard将于9月12日卸任
美股速递 · 08-20
PDS Biotechnology宣布CFO Lars Boesgaard将于9月12日卸任
PDS生物技术公司宣布战略重组:聚焦PDS0301进军转移性结直肠癌,并为PDS0101制定合作策略
美股速递 · 08-11
PDS生物技术公司宣布战略重组:聚焦PDS0301进军转移性结直肠癌,并为PDS0101制定合作策略
PDS Biotechnology宣布终止对PDS0101三期Versatile-003试验的内部投资
美股速递 · 08-11
PDS Biotechnology宣布终止对PDS0101三期Versatile-003试验的内部投资
PDS Biotechnology Corporation公布NCI主导的转移性结直肠癌二期临床试验第一阶段积极中期数据
美股速递 · 04-15
PDS Biotechnology Corporation公布NCI主导的转移性结直肠癌二期临床试验第一阶段积极中期数据
加载更多
公司概况
公司名称:
PDS Biotechnology Corporation
所属市场:
NASDAQ
上市日期:
--
主营业务:
PDS Biotechnology Corporation于2009年1月22日根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司,专注于发现,开发和寻求商业化的新颖的以医院为基础的治疗方案,能够改变治疗模式和危及生命的管理。
发行价格:
--
{"stockData":{"symbol":"PDSB","market":"US","secType":"STK","nameCN":"PDS Biotechnology Corporation","latestPrice":0.2201,"timestamp":1788537784083,"preClose":0.22,"halted":0,"volume":794595,"delay":0,"changeRate":0.0004545454545454045,"floatShares":54404300,"shares":55815700,"eps":-0.640141,"marketStatus":"交易中","change":0.0001,"latestTime":"09-04 12:06:54 EDT","open":0.22,"high":0.2378,"low":0.2174,"amount":178640.33141325,"amplitude":0.092727,"askPrice":0.2219,"askSize":200,"bidPrice":0.22,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.640141,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1788552000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1443672000000,"exchange":"NASDAQ","adjPreClose":0.22,"preHourTrading":{"tag":"盘前","latestPrice":0.22,"preClose":0.22,"latestTime":"08:54 EDT","volume":14373,"amount":3100.8962734200004,"timestamp":1788526486901,"change":0,"changeRate":0,"amplitude":0.095909},"postHourTrading":{"tag":"盘后","latestPrice":0.2216,"preClose":0.22,"latestTime":"19:30 EDT","volume":3114,"amount":680.1953,"timestamp":1788478204624,"change":0.0016,"changeRate":0.007273,"amplitude":0.019545},"volumeRatio":2.249575,"impliedVol":1.0437,"impliedVolPercentile":0.8968},"requestUrl":"/m/hq/s/PDSB","defaultTab":"news","newsList":[{"id":"1195092528","title":"PDS生物技术公司宣布解除Stephan Toutain首席运营官职务,自2026年8月21日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1195092528","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195092528?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:11","pubTimestamp":1787688689,"startTime":"0","endTime":"0","summary":"PDS生物技术公司(PDS Biotechnology Corporation)近日向美国证券交易委员会提交的文件显示,公司已正式解除Stephan Toutain的首席运营官职务。这一人事变动将于2026年8月21日正式生效。\n据披露文件确认,此次管理层调整已尘埃落定。Toutain的离任,标志着该公司在运营领导层方面迎来新的变动节点。\n值得关注的是,这一决定正值公司发展的关键时期。PDS生物技术作为一家专注于免疫疗法研发的创新型企业,其管理团队的调整无疑将引发市场各方的密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190128204","title":"PDS Biotechnology宣布裁员计划,优化资源配置以聚焦战略重点","url":"https://stock-news.laohu8.com/highlight/detail?id=1190128204","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190128204?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:11","pubTimestamp":1787688669,"startTime":"0","endTime":"0","summary":"8月6日,PDS Biotechnology Corporation(PDSB)通过美国证券交易委员会(SEC)文件披露,公司已正式批准一项人员精简方案。此举旨在调整运营成本结构,使其与既定战略优先事项保持一致。这家生物技术企业正通过削减人力开支,来应对当前阶段的资金配置需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195451064","title":"PDS Biotechnology宣布CFO Lars Boesgaard将于9月12日卸任","url":"https://stock-news.laohu8.com/highlight/detail?id=1195451064","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195451064?lang=zh_cn&edition=full","pubTime":"2026-08-20 04:56","pubTimestamp":1787172970,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation(纳斯达克代码:PDSB)今日向美国证券交易委员会(SEC)提交的文件显示,公司首席财务官(CFO)、首席财务主管及首席会计主管Lars Boesgaard将于9月12日正式卸任。\n这一高层人事变动在SEC文件中得以披露,标志着该公司财务管理层将迎来新的调整期。Boesgaard的离职生效日期恰逢9月中旬,为公司留出了一定的过渡与交接时间。\nPDS Biotechnology作为一家专注于免疫疗法研发的生物技术企业,此番核心财务高管更迭备受市场关注。截至目前,公司尚未公布继任者的具体人选或相关过渡安排,外界或将继续关注其后续动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133631174","title":"PDS生物技术公司宣布战略重组:聚焦PDS0301进军转移性结直肠癌,并为PDS0101制定合作策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1133631174","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133631174?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:26","pubTimestamp":1786451201,"startTime":"0","endTime":"0","summary":"PDS生物技术公司(PDS Biotechnology Corporation)近日正式对外宣布一项重大战略调整。此次重组表明,公司将把研发重心全力倾斜至其核心候选药物PDS0301之上,目标直指转移性结直肠癌(mCRC)这一严峻的适应症领域。与此同时,针对另一款关键在研产品PDS0101,管理层也已明确规划出一条全新的合作路径,冀望通过外部联盟来加速其临床开发与商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDSB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116772975","title":"PDS Biotechnology宣布终止对PDS0101三期Versatile-003试验的内部投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1116772975","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116772975?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:26","pubTimestamp":1786451169,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation(代码:PDSB)披露,已决定停止对PDS0101三期Versatile-003临床试验的内部资金投入。这一战略调整意味着,这家生物科技公司不再继续为该项关键试验提供内部资本支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PDSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116114948","title":"PDS Biotechnology Corporation公布NCI主导的转移性结直肠癌二期临床试验第一阶段积极中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1116114948","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116114948?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:46","pubTimestamp":1776257183,"startTime":"0","endTime":"0","summary":"PDS Biotechnology Corporation宣布,其PDS01ADC在由国家癌症研究所(NCI)主导的转移性结直肠癌(MCRC)二期临床试验第一阶段的中期研究数据已正式发表。此次公布的数据显示积极的临床效果,为后续治疗方案的推进提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDSB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pdsbiotech.com","stockEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":-0.6944},{"period":"3month","weight":-0.7843},{"period":"6month","weight":-0.6731},{"period":"1year","weight":-0.8308},{"period":"ytd","weight":-0.7142}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PDS Biotechnology Corporation于2009年1月22日根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司,专注于发现,开发和寻求商业化的新颖的以医院为基础的治疗方案,能够改变治疗模式和危及生命的管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.025289},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.061437},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.164348},{"month":4,"riseRate":0.454545,"avgChangeRate":0.079515},{"month":5,"riseRate":0.545455,"avgChangeRate":0.158069},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.000335},{"month":7,"riseRate":0.545455,"avgChangeRate":0.070482},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.072928},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.068665},{"month":10,"riseRate":0.3,"avgChangeRate":-0.019658},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.002317},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.051726}],"exchange":"NASDAQ","name":"PDS Biotechnology Corporation","nameEN":"PDS Biotechnology Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PDS Biotechnology Corporation(PDSB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PDS Biotechnology Corporation(PDSB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PDS Biotechnology Corporation,PDSB,PDS Biotechnology Corporation股票,PDS Biotechnology Corporation股票老虎,PDS Biotechnology Corporation股票老虎国际,PDS Biotechnology Corporation行情,PDS Biotechnology Corporation股票行情,PDS Biotechnology Corporation股价,PDS Biotechnology Corporation股市,PDS Biotechnology Corporation股票价格,PDS Biotechnology Corporation股票交易,PDS Biotechnology Corporation股票购买,PDS Biotechnology Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PDS Biotechnology Corporation(PDSB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PDS Biotechnology Corporation(PDSB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}